Norway· NO-ID_3AC26079-ED96-4593-A3E9-98367B62F296
Kyntheum
A brodalumab product containing brodalumab, registered in Norway by LEO PHARMA A/S (Danmark). The same ATC class is registered in 13 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Brodalumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AC12 (brodalumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Brodalumab · ATC L04AC12
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Brodalumab
- Manufacturer
- LEO PHARMA A/S (Danmark)
- Country
- Norway (NO)
- ATC code
- L04AC12
- ATC class
- Brodalumab
- Defined daily dose
- 15 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_3AC26079-ED96-4593-A3E9-98367B62F296
- no_varenummer5881342 x 1.5NOK 15986.5
- gtin5702191020649
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
59 interactions on record for brodalumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Brodalumab · interactions on record
59 records
- 27 severe
- 25 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Brodalumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKYNTHEUMLEO Pharma A/S, Ballerup
- BelgiumKyntheum 210 mgLeo Pharma
- SpainKYNTHEUM 210 MG SOLUCION INYECTABLE EN JERINGA PRECARGADALeo Pharma A/S
- IcelandKyntheumLEO Pharma A/S*
- PolandKyntheumLEO Pharma A/S
- SwedenKyntheum 210 mg Injektionsvätska, lösning i förfylld sprutaLEO Pharma A/S
- Japanブロダルマブ（遺伝子組換え）協和キリン
- United StatesSiliqBausch Health US LLC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Kyntheum
- Iceland · Kyntheum
- Liechtenstein · Kyntheum
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/43b24238-04b0-4939-8af2-9f45c40a4bb0 GET /v1/drugs/43b24238-04b0-4939-8af2-9f45c40a4bb0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning i ferdigfylt sprøyte",
"source": "fest",
"status": "A",
"atc_name": "Brodalumab",
"merkevare_id": "ID_3AC26079-ED96-4593-A3E9-98367B62F296",
"name_form_strength": "Kyntheum inj, oppl 210 mg/sprøyte",
"prescription_group": "C"
}See everything about brodalumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.